Drug Trial News

RSS

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.

29 Jan 2016

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

The first clinical trial to move forward as part of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team will target metastatic colorectal cancer, the second leading cause of cancer deaths among men and women combined in the U.S.

29 Jan 2016

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.

29 Jan 2016

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.

28 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX Technologies, Inc., a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer.

26 Jan 2016

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

The oral drug ivacaftor appears to be safe and could be beneficial to young children between the ages of 2 and 5 with a specific type of cystic fibrosis, according to new research published in The Lancet Respiratory Medicine journal.

22 Jan 2016

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

19 Jan 2016

Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

Experts from Children's Hospital Colorado (Children's Colorado) co-led a team of researchers in studying new approaches to reducing fall asthma exacerbations in pediatric patients.

18 Jan 2016

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

In an international first, people with lung cancer will find out if a new combination of drugs can kick-start their bodies' ability to fight back against the disease. They'll be part of a clinical trial now enrolling participants at the Medical University of South Carolina.

18 Jan 2016

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH's National Institute of Allergy and Infectious Diseases (NIAID).

17 Jan 2016

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).

13 Jan 2016

Drug Trial News

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Immunotherapy could be the future of cancer treatments

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Study explores new approaches to prevent fall asthma exacerbations in pediatric patients

MUSC starts enrolling participants in clinical trial to evaluate two drugs for non-small cell lung cancer

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News